Protocol Ledger

NCT05231629 · Phase II · ACTIVE NOT RECRUITING

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

Interventional Phase II clinical trial protocol NCT05231629 sponsored by University of Alabama at Birmingham in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-13 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05231629
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05231629
Protocol FieldVerified Registry Value
NCT IdentifierNCT05231629
Consolidated Lead SponsorUniversity of Alabama at Birmingham
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2023-12-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI